Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313897 · ClinicalTrials.gov registry record · Phase 2
UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01313897 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 10 participants.
The verdict
NCT01313897, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the therapeutic efficacy of the exp-NK cell therapy in research participants with relapsed high risk MM \[defined as gene expression profile (GEP) 70 gene score ≥0.66 and/or metaphase chromosomal abnormalities and/or high LDH ≥ 360U/L\] by establishing the (near) complete response rate. Response rate will be compared to case matched historical controls (patients who relapsed on Total Therapy 2 or 3 with high-risk MM defined as above). Disease-free survival and overall survival will be captured but are not primary or secondary endpoints.
Interventions
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-01 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01313897
The ClinicalTrials.gov registry entry for NCT01313897 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bortezomib is the first listed.
NCT01313897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01313897 about?
NCT01313897 is a clinical study titled "UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma". The purpose of this study is to determine the therapeutic efficacy of the exp-NK cell therapy in research participants with relapsed high risk MM \[defined as gene expression profile (GEP) 70 gene score ≥0.66 and/or metaphase chromosomal abnormalities and/or high LDH ≥ 360U/L\] by establishing the (...
What is the current status of trial NCT01313897?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2011-01. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01313897?
The interventions under investigation include: Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01313897?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.